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Prothymosin alpha (ProTa) suppresses stress-induced necrosis of cultured cortical neurons. As neuro-
protection alone could not explain the long-lasting protective actions against cerebral ischemia by ProTa,
we further examined whether ProTa, in addition to neuroprotective effects, has other anti-ischemic
activities. When recombinant mouse ProTa (rmProTa) at 0.3 mg/kg was intravenously (i.v.) given 2 h
after the start of tMCAO, all mice survived for more than 14 days. In evaluation of CD31- and tomato
lectin-labeling as well as IgG and Evans blue leakage, rmProTa treatment (0.1 mg/kg) largely blocked
ischemia-induced vascular damages. Therefore, rmProTa has novel beneﬁcial effects against ischemia-
induced brain damage through vascular mechanisms.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Nuclear protein prothymosin alpha (ProTa) is extracellularly
released from neuronal cells upon ischemic or starving stress and
protects neurons in an autocrinic or paracrinic manner (1e4).
Accordingly, ProTa is supposed to possess a nature of damage-
associated molecular patterns (DAMPs), but it has robustness ac-
tions to keep the cellular survival against different aspects of stress
(3e5). ProTa has been identiﬁed as an anti-necrosis factor from the
conditioned medium of serum- and supplement-free primary cul-
ture of rat embryonic cortex (1,3,6). In the culture of cortical neu-
rons, one of underlying molecular mechanisms was evidenced by
ProTa-mediated externalization of glucose transporter 1 and 4,
which had been endocytosed by ischemic or starving stress (1e3).
This mechanism prevents the necrotic energy crisis due to cellular
ATP loss (1,2). Additional anti-necrotic mechanism by ProTa is
related to the activation of caspase 3, which cleaves poly (ADP-
ribose) polymerase, resulting in the suppression of necrotic cell
death by inhibiting a rapid decrease in mitochondrial ATPgG, immunoglobulin G; i.p.,
alpha; TEV, tobacco etch vi-
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d/4.0/).production (3,7,8). However, ProTa remarkably protects the
ischemic brain (9). Detailed analyses revealed that ProTa in vivo
inhibits not only necrosis, but also apoptosis by a help of endoge-
nous brain-derived neurotrophic factor or erythropoietin (2,3,10).
Similar mechanisms of necrosis inhibition and neurotrophic factor-
mediated apoptosis inhibition were also observed in retinal ische-
miaereperfusion model (11). Furthermore, in vivo protective roles
of ProTa were evidenced in experiments using treatments with
neutralizing ProTa antibody or ProTa antisense oligonucleotide
(2,11).
In cerebral ischemia or stroke, the blockade of neuronal death
would be the most important endpoint for medicinal treatments.
However, neuroprotection alone is not enough for successful
treatments, since neuroinﬂammation due to microvascular occlu-
sion may persistently causes neuronal damages (12). As systemic
administration of ProTa remarkably protects the ischemic brain for
longer periods (9), but neuroprotective function alone could not
explain the long-lasting protective actions against cerebral
ischemia by ProTa, we hypothesize that ProTa might have addi-
tional beneﬁcial effects against cerebral ischemia. In the present
study, we attempted to examine the effects of ProTa on vascular
damages by cerebral ischemia.
Male C57BL/6J 6-week-old mice weighing 20e24 g were pur-
chased from TEXAM Corporation (Nagasaki, Japan) and used for all
experiments. Mice were kept in a room maintained at temperature
of 21 ± 2 C and relative humidity of 55 ± 5%with a 12eh light/darknese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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water. All experiments were approved by the Nagasaki University
Animal Care Committee (Nagasaki, Japan).
Mouse recombinant ProTa (rmProTa), V8 serine protease (V8)-
digested rmProTa and V8 were diluted in phosphate-buffered sa-
line (PBS). Mice were intravenously (i.v.) treated with rmProTa
(0.03, 0.1, or 0.3 mg/kg), V8-digested rmProTa (0.1 or 0.3 mg/kg), V8
(2.5 or 7.5 mg/kg) or PBS (vehicle) 1, 2, 3, or 4 h after the start of
cerebral ischemia induced by transient middle cerebral artery oc-
clusion (1 h tMCAO). The details of tMCAO, ProTa preparation and
its proteolysis by V8 protease, western blotting, tissue preparation,
histological analysis, labeling of blood vessels with Lycopersicon
esculentum (tomato) lectin and cluster of differentiation 31 (CD31),
detection of endogenous immunoglobulin G (IgG) leakage, Evans
blue extravasation, and behavioral assessments were provided in
Supplementary materials and methods.
Statistical analyses were performed using TukeyeKramer mul-
tiple comparison post-hoc analysis after a one-way analysis of
variance (ANOVA). Survival ratio was analyzed by Log-rank test
after KaplaneMeier survival plots using GraphPad Prism 6 soft-
ware. Results are shown as means ± standard error of the mean
(S.E.M). p < 0.05 was considered signiﬁcant.
As shown in Supplementary Fig. 1, rmProTa was prepared by
sequential methodological steps including PCR ampliﬁcation of
tobacco etch virus (TEV)-ProTa, insertion of TEV-ProTa into the
pGEX4T1 expression vector, transformation of pGEX4T1-TEV-ProTa
into BL21 Escherichia coli (E. coli), lysis of BL21 E. coli cells, and
puriﬁcation of rmProTa through glutathione sepharose column,
Mono Q ion-exchange column and Centriprep YM-3 ﬁlter.
Following removal of endotoxin contamination by EndTrap afﬁnity
system, rmProTa was ﬁnally dialyzed against PBS. We obtained
0.9 mg rmProTa in 3 ml of PBS from 4 l of Luria broth culture me-
dium as the initial volume. The endotoxin level in puriﬁed rmProTa
was 0.09 EU/ml (0.9 EU/kg). When sample fractions at different
puriﬁcation steps were run on sodium dodecyl sulphate (SDS)-
polyacrylamide gel, a band for rmProTa (12.5 kDa) was detected by
staining the SDS-polyacrylamide gel with Coomassie Brilliant Blue
(CBB) (Fig. 1A). A band for rmProTawas disappeared in CBB-stained
SDS-polyacrylamide gel when rmProTa was digested with V8
(Fig. 1B). The purity of rmProTa was also conﬁrmed by western
blotting using antibodies against N- and C-terminal sequences in
ProTa (Fig. 1C and 1D, respectively).
To determine the better condition for rmProTa administration
against cerebral ischemia, micewere treatedwith rmProTa (0.3mg/
kg, i.v.) 1, 2, 3, or 4 h after the start of tMCAO. Vehicle (PBS)-treated
mice died within 7 days after tMCAO (Fig. 2A). When rmProTa was
given 2 h after the start of tMCAO, all mice survived (signiﬁcant,
p < 0.01, Log-rank test) for more than 14 days (Fig. 2A). Signiﬁcant
effects in survival were also obtained by rmProTa administration at
1 h (signiﬁcant, p < 0.01), but not at 3 or 4 h (not signiﬁcant,
p > 0.05) after the start of tMCAO (Fig. 2A). Previous studies re-
ported that tMCAO-type cerebral ischemia caused motor dysfunc-
tion, which was evaluated by increase in neurological scores
(13,14). We also observed that neurological scores were signiﬁ-
cantly increased 4 and 7 days after the start of tMCAO, whereas
administration of rmProTa 2 h after the start of tMCAO markedly
decreased neurological scores 4 and 7 days after tMCAO (Fig. 2B).
Neurological scores were also signiﬁcantly decreased 7 days after
tMCAO when mice were treated with rmProTa 1 h, but not 3 or 4 h
after the start of tMCAO (Fig. 2B). ProTa-caused increase in survival
ratio and decrease in neurological scores were abolished in mice
treatedwith V8-digested rmProTa (0.3mg/kg, i.v.) 2 h after the start
of tMCAO (Fig. 2C and 2D, respectively).
To examine the dose-dependent protective activity of rmProTa
against cerebral ischemia, mice were treated (i.v.) with 0.03, 0.1, or0.3 mg/kg rmProTa 2 h after the start of tMCAO. Administration of
rmProTa at a dose of 0.3 mg/kg markedly reversed tMCAO-induced
increase in neurological scores 4 and 7 days after tMCAO (Fig. 2E).
Neurological scores were also signiﬁcantly decreased 7 days after
tMCAO when mice were treated with 0.1 mg/kg rmProTa, but not
with 0.03 mg/kg (Fig. 2E). Administration of V8-digested rmProTa
(0.3 mg/kg, i.v.) abolished ProTa-caused decrease in neurological
scores 4 and 7 days after tMCAO (Fig. 2E). However, V8 alone did
not show any effects against tMCAO-induced decrease in survival
ratio (Fig. 2C) and increase in neurological scores (Fig. 2D, E).
To conﬁrm whether rmProTa treatment 2 h after the start of
tMCAO protects the brain from ischemic damages, histological
analysis using Nissl staining of brain sections was performed 24 h
after tMCAO. We observed that the ischemic core was clearly
demarcated from the surrounding brain region (penumbra), and
Nissl-stained neuronal cells were shrunken in the regions of ipsi-
lateral striatum and somatosensory cortex 24 h after tMCAO in
vehicle (PBS)-treated tMCAO mice (Supplementary Fig. 2A),
consistent with previous studies with brain ischemia (15,16). In
contrast, administration (i.v.) of 0.3 mg/kg rmProTa 2 h after the
start of tMCAO partially, but signiﬁcantly reduced infarct volume
from 49.9 ± 2.2 to 35.6 ± 4.8% (n ¼ 3) and inhibited shrunken of
neuronal cells 24 h after tMCAO, as shown in Supplementary Fig. 2A
and 2B.
Next, we examined whether ProTa has protective actions
against ischemia-induced vascular damages. Mice were treated
(i.v.) with rmProTa (0.1 mg/kg), or V8-digested rmProTa (0.1 mg/kg)
2 h after the start of tMCAO, and coronal brain sections (þ0.98 mm
from Bregma) were labeled with CD31 and tomato lectin, which are
considered as endothelial markers of blood vessels (17,18) as
described in Supplementarymaterials andmethods. The damage of
blood vessels in terms of disrupted labeling of CD31 and tomato
lectin was observed in the region of somatosensory cortex 24 h
after tMCAO (Fig. 3A and Supplementary Fig. 3A, B). Moreover, the
length of blood vessels was signiﬁcantly decreased 24 h after
tMCAO (Fig. 3B). Administration of rmProTa signiﬁcantly inhibited
ischemia-induced damage of blood vessels 24 h after tMCAO
(Fig. 3A, B and Supplementary Fig. 3A, B). ProTa-caused inhibition
of cerebral vascular damages was abolished when mice were
treated with V8-digested rmProTa 2 h after the start of tMCAO
(Fig. 3A, B and Supplementary Fig. 3A, B).
Several recent studies reported that cerebral ischemia caused
vascular disruption/permeability in the evaluation of endogenous
immunoglobulin G (IgG) or Evans blue leakage in the brain of mice
and rats (19e23). Based on previous reports and our present ﬁnd-
ings using CD31 and tomato lectin labeling, we further conducted
quantitative analysis of endogenous IgG and Evans blue leakage
following tMCAO to explore whether ProTa blocks cerebral
ischemia-induced vascular disruption/permeability. Mice were
treated (i.v.) with rmProTa (0.1 mg/kg), V8-digested rmProTa
(0.1 mg/kg), or V8 alone 2 h after the start of tMCAO, and endog-
enous IgG or Evans blue leakage was assessed 24 h after tMCAO.
Immunostaining revealed that IgG was markedly leaked after
tMCAO, whereas administration of rmProTa signiﬁcantly reduced
the leakage of IgG (Fig. 3C, D). ProTa-caused inhibition of IgG
leakage following tMCAO was abolished when mice were treated
with V8-digested rmProTa (Fig. 3C, D). Similarly, administration of
rmProTa signiﬁcantly reduced tMCAO-induced leakage of Evans
blue 24 h after tMCAO (Fig. 3C, E). Administration of V8-digested
rmProTa abolished ProTa-caused reduction of Evans blue leakage
24 h after tMCAO (Fig. 3C, E). However, V8 alone had no effects on
tMCAO-induced leakage of IgG or Evans blue 24 h after tMCAO
(Fig. 3CeE).
Recombinant mouse ProTa (rmProTa) at 0.3 mg/kg (i.v.) showed
potent survival effects in mice with tMCAO (1 h)-type cerebral
Fig. 1. Preparation of recombinant mouse ProTa (rmProTa). (A) SDS-polyacrylamide gel electrophoresis analysis of the rmProTa purity at different puriﬁcation steps. Samples were
run on a 15% polyacrylamide gel and subsequently stained with CBB. M, protein marker; lane 1, supernatants of disrupted BL21 E. coli by Nonidet-P40 lysis buffer and sonication;
lane 2, the ﬂow-through of sample 1 through glutathione sepharose column; lane 3, the washed fraction of sample 2; lane 4, the eluates by glutathione elution buffer; lane 5, TEV
protease digests of sample 4; lane 6, the ﬂow-through of sample 5 with glutathione sepharose column; lane 7, rmProTa puriﬁed with a Mono Q column puriﬁed of sample 6; lane 8,
the concentrated solution of sample 7 with a Centriprep YM-3; lane 9, the ﬂow-through of sample in the Centriprep YM-3; lane 10, treatment of sample 8 with EndTrap blue kit to
remove endotoxin; lane 11, dialysis of sample 10 with PBS. (B) SDS-polyacrylamide gel was loaded with rmProTa (1 mg/lane) and V8-digested rmProTa (1 mg/lane). The band of
rmProTa (12.5 kDa) was detected by CBB staining of SDS-polyacrylamide gel and using a protein marker (M). ProTa band was not observed when rmProTa was digested with V8. (C,
D) For western blotting, SDS-polyacrylamide gel was loaded with rmProTa (1 mg/lane) and V8-digested rmProTa (1 mg/lane). Detection of rmProTa was performed using antibodies
against N-terminus ProTa (C) and C-terminus ProTa (D).
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cial administration schedule of rmProTa was 2 h after the start of
cerebral ischemia, and all mice survived for more than 14 days.
Similar results of critical periods for rmProTa effects were also
observed in the evaluation of neurological scores. Moreover, his-
tological analysis using Nissl staining conﬁrmed that rmProTa
administration 2 h after the start of tMCAO signiﬁcantly reduced
infarct volume and inhibited neuronal damage. We previously re-
ported that signiﬁcant amount of Myc-tagged recombinant ratProTa (i.v.) was observed only in ischemic hemisphere in the brain
(9), suggesting the efﬁcient brain penetration of ProTa requires
ischemia-induced bloodebrain barrier damage. This view may
explain the fact that rmProTa treatment at 1 h after the start of
ischemia shows weaker effects than that at 2 h.
The fact that rmProTa-induced complete survival effects after
ischemic stroke suggests that ProTamay have additional beneﬁcial
effects against cerebral vascular damages in addition to direct
survival effects against neuronal cell death (1,3,9), since blood
Fig. 2. Therapeutic period of ProTa treatment against cerebral ischemia. (A, B) Recombinant mouse ProTa (rmProTa) was administered (i.v.) 1, 2, 3, or 4 h after the start of cerebral
ischemia (tMCAO) in mice. Vehicle (Veh) represents PBS injection (i.v.) 1 h after the start of tMCAO. Evaluation of survival ratio (A) and neurological scores (B) after tMCAO. n ¼ 8. (C,
D) PBS (vehicle), rmProTa, V8-digested rmProTa, or V8 alone was injected (i.v.) 2 h after the start of tMCAO. Evaluation of survival ratio (C) and neurological scores (D) following
tMCAO. n ¼ 8. (E) Following PBS (vehicle), rmProTa, V8-digested rmProTa, or V8 administration (i.v.) 2 h after the start of tMCAO, the neurological scores were assessed 4 and 7 days
after tMCAO. n ¼ 8. Data are means ± S.E.M. *, #p < 0.05, **, ##p < 0.01.
Fig. 3. ProTablocks cerebral ischemia-induced vascular damages. (A, B)Micewere treated (i.v.)with PBS (vehicle), rmProTa (0.1mg/kg) or V8-digested rmProTa (0.1mg/kg) 2h the start
of after cerebral ischemia (1 h tMCAO). (A) Representative merged images showing somatosensory cortex 1 (S1) in the brain (þ0.98 mm from Bregma) labeled with CD31 and tomato
lectin 24h after tMCAO (CD31, red; tomato lectin, green). (B) Quantitative analysis of the length of blood vesselswithmerged images of tomato lectin andCD31 at 24h after tMCAO.Data
were obtained from3 independentmice for each group. (CeE)Micewere treated (i.v.)with PBS (vehicle), rmProTa (0.1mg/kg), V8-digested rmProTa (0.1mg/kg) or V8 alone2h after the
start of cerebral ischemia (1 h tMCAO). (C) Representative images showingdetection of endogenous IgG leakage (left panels) and Evans blue leakage (right panels) 24 h after tMCAO. (C)
Quantitative analysis of endogenous IgG leakage 24 h after tMCAO. n¼ 3. (D) Quantitative analysis of Evans blue leakage 24 h after tMCAO. n¼ 5. Data aremeans ± S.E.M. *, #, yp< 0.05.
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were still observed 24 h after tMCAO. Surprisingly, systemic
administration of rmProTa at 0.1 mg/kg 2 h after the start of tMCAO
caused a potent inhibition of blood vessel damages 24 h after
tMCAO. The beneﬁcial effects of rmProTawere also observed in the
evaluation of IgG or Evans blue leakage after tMCAO. Although
rmProTa-caused neuronal protection was partial in histological
assessment, strong vascular protection against tMCAO was ob-
tained by rmProTa treatment. In the present study, IgG leakage
indicates the total vascular damages till 24 h after tMCAO, while
Evans blue leakage does the weakness of blood brain barrier during
the period between 22 and 24 h after tMCAO. Therefore, these re-
sults suggest that rmProTa inhibits unidentiﬁed molecular mech-
anisms causing at least 24-h long vascular damages as well as
neuroprotective effects at early phase after ischemia. Further
studies to examine the direct effects of rmProTa on cultured
endothelial cells, and brain and peripheral inﬂammatory cells,
would clarify the molecular mechanisms of rmProTa-induced
beneﬁcial effects against stroke.
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